Vera Therapeutics, Inc.
VERANasdaq
$38.50
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↑ +63.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.8B
Enterprise Value
$2.2B
P/E
—
P/S
—
P/B
5.5
EV/EBITDA
—
PEG
—
FCF Yield
-10.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$369.0M
Free Cash Flow (TTM)
-$293.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-73.8%
ROIC
—
Debt / Equity
0.2
Net Cash
$521.7M
Return 1Y
+62.0%
Company profile
Vera Therapeutics, Inc. focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for immunoglobulin A nephropathy.
- CEO
- Marshall W. Fordyce
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- veratx.com
Management & directors
- Fordyce MarshallPRESIDENT AND CEO
- Mitchell Jane WrightChief Legal Officer
- Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
- Brenner RobertChief Medical Officer
- Grant SeanCHIEF FINANCIAL OFFICER
- Johnson David LeeChief Operating Officer
- Skelton Laurence MatthewChief Commercial Officer
- Turner William D.Chief Regulatory Officer
- Carter Jason SChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
VERA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.69↑ +108.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$52.2M | -$34.4M | -$90.9M | -$102.0M | -$167.2M | -$315.5M |
| Net income | -$53.4M | -$32.6M | -$89.1M | -$96.0M | -$152.1M | -$299.6M |
| Diluted EPS | — | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
| Operating cash flow | -$34.8M | -$23.7M | -$67.6M | -$92.2M | -$134.7M | -$241.1M |
| Free cash flow | -$34.9M | -$23.7M | -$67.7M | -$92.2M | -$135.7M | -$241.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$37.3M | -$49.8M | -$48.9M | -$57.2M | -$80.1M | -$83.9M | -$94.2M | -$125.1M |
| Net income | -$33.7M | -$46.6M | -$43.4M | -$51.7M | -$76.5M | -$80.3M | -$91.1M | -$121.0M |
| Diluted EPS | -$0.62 | -$0.85 | -$0.72 | -$0.81 | -$1.20 | -$1.26 | -$1.39 | -$1.69 |
| Operating cash flow | -$24.8M | -$36.9M | -$39.2M | -$54.4M | -$54.8M | -$61.9M | -$70.0M | -$106.5M |
| Free cash flow | -$24.9M | -$37.1M | -$39.8M | -$54.6M | -$55.0M | -$62.0M | -$70.1M | -$106.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 11, 2026
Jul 10, 2026
- 10d agoVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com
- 10d agoIs FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?finance.yahoo.com
- 10d agoVera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approvalfinance.yahoo.com
- 10d agoVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Runfinance.yahoo.com
Jul 7, 2026
- 13d agoSector Update: Healthcare Stocks Gain Late Afternoonfinance.yahoo.com
- 13d agoVERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeuticsstocktwits.com
- 13d agoVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathyfinance.yahoo.com
- 13d agoVera Therapeutics wins FDA nod for closely watched kidney disease drugbiopharmadive.com
Jul 6, 2026
- 14d agoVera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)investorshub.advfn.com
- 14d agoScilex, Vera Therapeutics rise premarket; Strategy gainsfinance.yahoo.com
- 14d agoVERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upsidestocktwits.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 32,550 | $42.07 | $1.4M | filing |
| 2026-07-07 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 10,500 | $42.86 | $450,006.90 | filing |
| 2026-07-07 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 2,200 | $43.59 | $95,908.34 | filing |
| 2026-07-07 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 1,000 | $40.78 | $40,776.20 | filing |
| 2026-06-23 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 18,412 | $37.93 | $698,387.41 | filing |
| 2026-06-23 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 88 | $38.43 | $3,381.84 | filing |
| 2026-05-12 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 14,219 | $36.64 | $520,978.47 | filing |
| 2026-05-12 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 4,281 | $37.09 | $158,768.59 | filing |
| 2026-04-14 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 14,130 | $43.66 | $616,985.04 | filing |
| 2026-04-14 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 7,921 | $44.58 | $353,105.51 | filing |
| 2026-04-14 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 900 | $45.51 | $40,960.26 | filing |
| 2026-03-23 | Mitchell Jane Wright· Chief Legal Officer | Award | 42,403 | $0.00 | $0.00 | filing |
| 2026-03-13 | Young Joseph R· SVP, FINANCE, CHIEF ACCT OFFCR | Option exercise | 10,000 | $3.94 | $39,396.00 | filing |
| 2026-02-23 | Fordyce Marshall· PRESIDENT AND CEO | Sale | 16,925 | $41.98 | $710,577.51 | filing |
| 2026-02-23 | Grant Sean· CHIEF FINANCIAL OFFICER | Sale | 4,949 | $41.98 | $207,778.32 | filing |
| 2026-02-23 | Young Joseph R· SVP, FINANCE, CHIEF ACCT OFFCR | Sale | 3,117 | $41.98 | $130,863.82 | filing |
| 2026-02-23 | JOHNSON DAVID LEE· Chief Operating Officer | Sale | 2,579 | $41.98 | $108,276.48 | filing |
| 2026-02-23 | Turner William D.· Chief Regulatory Officer | Sale | 2,187 | $41.98 | $91,818.79 | filing |
| 2026-02-23 | Brenner Robert· Chief Medical Officer | Sale | 2,151 | $41.98 | $90,307.37 | filing |
| 2026-02-23 | Skelton Laurence Matthew· Chief Commercial Officer | Sale | 1,582 | $41.98 | $66,418.53 | filing |
| 2026-02-04 | Young Joseph R· SVP, FINANCE, CHIEF ACCT OFFCR | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Fordyce Marshall· PRESIDENT AND CEO | Award | 68,800 | $0.00 | $0.00 | filing |
| 2026-02-04 | Grant Sean· CHIEF FINANCIAL OFFICER | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Skelton Laurence Matthew· Chief Commercial Officer | Award | 20,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Turner William D.· Chief Regulatory Officer | Award | 25,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.